Clinical Trials Directory

Trials / Completed

CompletedNCT05076890

Hemp 15 mg & 50 mg Capsule Absorption

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Gaia Herbs Inc. · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study is intended to investigate the absorption of cannabidiol (CBD) and cannabidiol acid (CBD-A) in plasma from an oral delivery of a single dose of full spectrum hemp extract at two concentrations over a 4-hour timeline.

Detailed description

This study is designed to determine the time to maximum plasma concentration of CBD and CBD-A after an oral dose of standardized full spectrum hemp extract over a 4-hour timeline. This study is designed to include two arms. Each arm will be delivered a different concentration of standardized full spectrum hemp extract, either 15 mg or 50 mg. Throughout the course of the study all participants will be asked to provide four (4) plasma samples, 10 randomly selected participants will be asked to provide five (5) plasma samples. Samples will then be evaluated using a validated LC-MS/MS method to develop a blood concentration time curve in order to determine time to reach maximum blood concentration. This trial is double-blinded with two arms enrolling only healthy individuals. The participants randomized for a fifth blood draw will be randomly selected from these two arms.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENT15 mg/g Full Spectrum Hemp ExtractHPMC capsules containing full spectrum standardized hemp extract in liquid form.
DIETARY_SUPPLEMENT50 mg/g Full Spectrum Hemp ExtractHPMC capsules containing full spectrum standardized hemp extract in liquid form.

Timeline

Start date
2021-08-26
Primary completion
2022-03-26
Completion
2022-03-26
First posted
2021-10-13
Last updated
2023-02-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT05076890. Inclusion in this directory is not an endorsement.